The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease

Borst, Bram van den; Gosker, Harry R.; Koster, Annemarie; Yu, Binbing; Kritchevsky, Stephen B.; Liu, Yongmei; Meibohm, Bernd; Rice, Thomas B.; Shlipak, Michael G.; Yende, Sachin; Harris, Tamara B.; Schols, A.M.W.J.

doi:10.3945/ajcn.112.040774

Cited by 84 publications

(103 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, a recent population study demonstrated an association between sarcopenia and metabolic syndrome in male COPD patients [11]. Although conclusive data were not available in the present study, abdominal obesity was accompanied by higher CRP-levels, corresponding with recent data indicating that excessive abdominal FM contributes to the systemic inflammation in COPD, which in turn is an important risk factor for cardiovascular disease [4,34]. Albeit abdominal obesity seem to be protective in the present study, the effect on cardiovascular co-morbidity should be further evaluated in subsequent study in order to be able to point out the net effect of this phenotype.…”

Section: Discussionsupporting

confidence: 57%

Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD

et al. 2015

View full text Add to dashboard Cite

Decreased physical performance due to loss of muscle mass (i.e. sarcopenia) is prevalent in ageing and appears more pronounced in chronic disease. A comprehensive profile of the sarcopenic phenotype in chronic obstructive pulmonary disease (COPD) is not yet available. The aim of the present study was to characterise prevalence, functional implications and predictive value of sarcopenia with or without abdominal obesity in Dutch COPD patients eligible for pulmonary rehabilitation.505 COPD patients (aged 37-87 years; 57% male) underwent assessment of lung function, body composition and physical functioning, before entering pulmonary rehabilitation. Sarcopenia was assessed by appendicular skeletal muscle index (ASMI) and abdominal obesity by android/gynoid percentage fat mass (A/G%FM) using dual energy X-ray absorptiometry.86.5% of patients were sarcopenic and showed lower physical functioning, while coexistent abdominal obesity (78.0%) resulted in higher physical functioning. Implications on endurance were less pronounced in women. The predictive value for physical functioning was higher for the "three-compartment" model (ASMI, bone mineral content and A/G%FM) than the "two-compartment" model (fat-free mass index and fat mass index) or "one-compartment" model (body mass index).In patients eligible for pulmonary rehabilitation, sarcopenia is highly prevalent in all body mass index categories and associated with impaired strength, and in men also with decreased endurance. Abdominal obesity seems to have protective effects on physical functioning. ASMI is a better predictor for physical functioning than fat-free mass index. @ERSpublications Highly prevalent sarcopenia and abdominal obesity in COPD patients exert antagonistic effects on physical functioning http://ow.ly/L5b9r

show abstract

Section: Discussionsupporting

confidence: 57%

Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD

et al. 2015

View full text Add to dashboard Cite

show abstract

“…COPD has been associated with increased risk of abdominal obesity (147,148). Although a high BMI has been paradoxically associated with improved survival in advanced COPD (131,149,150), overweight and obesity, particularly in their visceral forms, may not be beneficial in milder forms of COPD, as they may mask muscle wasting and be associated with cardiovascular and metabolic complications (151,152).…”

Section: American Thoracic Society Documentsmentioning

confidence: 99%

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Maltais¹,

Decramer²,

Casaburi³

et al. 2014

Am J Respir Crit Care Med

887

1,033

View full text Add to dashboard Cite

“…This could be relevant in COPD as Van den Borst et al . and Furutate et al recently reported a higher visceral adipose tissue in older‐age patients with COPD compared with age‐matched healthy controls, despite comparable subcutaneous adipose tissue and BMI 29, 30…”

Section: Recent Developments In Identifying Muscle Wasting In Copdmentioning

confidence: 94%

Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective

Sanders¹,

Kneppers²,

Bool³

et al. 2015

Journal of Cachexia, Sarcopenia and Muscle

119

101

View full text Add to dashboard Cite

Cachexia and muscle wasting are well recognized as common and partly reversible features of chronic obstructive pulmonary disease (COPD), adversely affecting disease progression and prognosis. This argues for integration of weight and muscle maintenance in patient care. In this review, recent insights are presented in the diagnosis of muscle wasting in COPD, the pathophysiology of muscle wasting, and putative mechanisms involved in a disturbed energy balance as cachexia driver. We discuss the therapeutic implications of these new insights for optimizing and personalizing management of COPD‐induced cachexia.

show abstract

The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease

Abstract: Our data suggest that excessive abdominal visceral fat contributes to increased plasma IL-6, which, in turn, is strongly associated with all-cause and cause-specific mortality in older persons with OLD.

Cited by 84 publications

References 57 publications

Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD

Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD

An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease

Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective

Contact Info

Product

Resources

About